text:
About ISCT | Join ISCT | Contact Us | Media
MSC Clinical Trial Updates
ISCT-CBA Cord Blood Series in Partnership with ASTCT
Cell Processing Track
Global Regulatory Perspectives Workshop
ISCT-FACT Cell Therapy Quality Bootcamp
Full Speaker List
Pre-Meeting Events (May 28)
Pre-Meeting GMP Facility Tours
Pre-Meeting Fact Accreditation Workshop
Wednesday May 29th
16:30 - 18:30: Corporate Symposium hosted by Miltenyi
Cutting-edge manufacturing solutions for advanced cell therapies
John Rasko, AO, BSc(Med), MBBS(Hons), PhD, Royal Prince Alfred Hospital, Australia
Amit Chandra, PhD, Innovation Supervisor Cell Therapy, Yposkesi SAS, France
Development of automated protocols for the production of iPSC derived therapies
Lin Yang, Prof., PhD, PersonGen BioTherapeutics (Suzhou) Co., Ltd., China
Automated manufacturing of chimeric antigen receptor T cells
Marcos de Lima, Prof., MD, University Hospitals Cleveland Medical Center, United States
Point of care manufacturing of anti-CD19 CAR T cells for lymphoma
19:45 - 20:00: Global Showcase Opening Address hosted by CCRM
CCRM: Collaborative, Capital-Efficient Commercialization of Regenerative Medicine – The Australian Connection
Michael May, PhD, President & CEO, Centre for Commercialization of Regenerative Medicine, Canada
Thursday May 30th
7:30 - 8:30: Breakfast Tutorial hosted by Cell Therapies Pty Ltd
Commercial, manufacturing and clinical aspects of a multinational rare disease gene therapy
Nathan Smith, Project Portfolio Manager, Cell Therapies Pty Ltd, Australia
Geoff Mackay, Chief Executive Officer, AvroBio, USA
Alexandra Rizzitelli, PhD, Cell Therapy Specialist, Cell Therapies Pty Ltd, Australia
Professor David Ritchie, MD PhD, Haematologist & Head of Allogeneic Stem Cell Transplantation, The Royal Melbourne Hospital, Australia
Conducting a multinational rare disease gene therapy clinical trial poses many challenges that must be overcome to ensure a successful clinical study. We will present a case study detailing the different aspects to the implementation of AVROBIO's phase 1/2 clinical study for their AVR-RD-01 product for patients with Fabry disease in Australia.
Initially, AVROBIO, a leader in lentiviral-based gene therapies, will review their corporate goals, the technology platform, the product, and the disease. Cell Therapies, a contract manufacturer based in Melbourne that supplies the clinical product, will provide details on the technology transfer and product manufacturing. Finally, the clinical aspects and patient considerations of the Fabry disease study will be outlined by The Royal Melbourne Hospital, who has been treating patients in Victoria for over 170 years.
7:30 - 8:30 Breakfast Tutorial hosted by Thermo Fisher Scientific
Overcoming challenges in cell therapy manufacturing
Randy Schweickart, Director of Engineering, Juno Therapeutics, Inc
Tia Hexom, Field Applications Scientist, Thermo Fisher Scientific
There are multiple challenges in the manufacture of T cell therapies that must be solved in order to meet the global commercialization need for these therapies. In this presentation, solutions to some of these challenges will be presented, including how to reduce variability in the donor's starting material by simultaneous isolation and activation of naïve and early memory T cells, which persists in vivo. Also, a solution to improve productivity and scalability with be presented that is xeno-free, serum- free, and scalable to meet workflow processes. Lastly, an industry leader, Juno Therapeutics, will discuss some key process challenges and mitigations to ensure robust and efficient commercial cell therapy manufacturing.
10:30 - 10:45: Global Showcase hosted by GE Healthcare
Solutions that enable efficiencies in cGMP manufacturing
Greg Crescenzi, Enterprise Solutions Leader, GEHC Cell and Gene Therapy, USA
GE Healthcare's cell and gene therapy flexible and scalable manufacturing solution with the FlexFactory™ platform is intended to improve cell therapy manufacturing. Working with customers GE provides drug developers with a flexible and scalable manufacturing platform suitable for early-stage clinical or commercial production. This session will provide an overview of some of the key manufacturing challenges associated with cell therapy and discuss how this new solution can help mitigate some of these challenges and reduce time to market
10:45 - 11:00: Global Showcase hosted by Sartorius Stedim Biotech
Engineered for Life – BIOSTAT ® RM TX with Flexsafe® RM TX for Culturing Consistent Quality Cellular Products
Ruth McDermott, Platform Manager Regenerative Medicine, Sartorius Stedim Biotech, UK
Sartorius has recently launched its new single used rocking motion bioreactor platform for the manufacture of cell therapy products.
The BIOSTAT® RM TX bioreactor system combined with Flexsafe® technology enables the ex vivo expansion of patient cells for cell immunotherapy applications. We will present how this platform has been designed for:
Consistent cell growth
Minimized risk of contamination
Improved manufacturing efficiency
Innovative cell harvesting
12:30 - 13:30: Corporate Tutorial hosted by GE Healthcare
Driving speed to market through collaboration
Phil Vanek, Ph.D., GM, Growth Strategy, GEHC Cell and Gene Therapy, USA
Dr. Robin Ng, Strategy Lead, Technology and Manufacturing, Shanghai Cellular Biopharmaceutical Group Ltd. (CBMG), China
Rohin Iyer, Ph.D., Development Manager, Cell and Gene Therapy, GEHC/FastTrak@CCRM
Greg Crescenzi, Enterprise Solutions Leader, GEHC Cell and Gene Therapy
Effective process development and robust manufacturing are key to scaling cell and gene therapies for commercialization. A flexible solution that offers both could provide a competitive advantage. Recently, Cellular Biomedicine Group (CBMG), a clinical stage biopharmaceutical company in Shanghai, China, partnered with GE Healthcare (GEHC)'s Enterprise Solutions team as well as the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto to develop a next-generation CAR-T process based on GE's FlexFactory equipment. Through a panel discussion they will discuss how these three teams worked together, with specific emphasis on how important logistical, technical and communication decisions were made to build a state-of-the-art CAR-T manufacturing facility/process that met CBMG's specifications and supported their IND filing to the Chinese FDA.
12:30 - 12:45: Global Showcase hosted by Australian Red Cross Blood Service
Beyond Blood – Supporting Cell Therapies from the bottom up
Shane Winzar, Australian Red Cross Blood Service, Australia
Augustin Raj, Australian Red Cross Blood Service, Australia
The Blood service has for many decades provided key support services to Australia's Cell Therapy, Precision Medicine and Regenerative Medicine industries, from public based research through to fully scaled commercial endeavors.
Our services and capabilities include provision of research grade blood components, set up of quality systems, Therapeutic Good licensing consultancy, screening of autologous and allogeneic donors, for HLA typing using Next Gen sequencing and other world class platforms. Additionally, we assist cGMP collections for provision of cell therapy based clinical trials.
The Blood Service is involved in collaborative R&D in CAR-T clinical trials and provides services direct to other clients to assist them in bringing their products to provide a greater contribution to healthcare for all Australians.
12:45 - 13:00: Global Showcase hosted by Regeneus Ltd
Regeneus' novel allogenic stem cell platforms for musculoskeletal and Neuropathic pain disorders
Charlotte Morgan, PhD, Head of R&D, Regeneus, USA
Regeneus is an Australian based clinical stage regenerative medicine company, focused on musculoskeletal and Neuropathic pain indications. Our leading technology platform Progenza is an Adipose derived MSC product combined with MSC secretions. A Phase 1 clinical study in Knee Osteoarthritis met primary and secondary endpoints in pain reduction and positive signs of disease modification. Positive pre-clinical pain study data has also been achieved in preparation for a clinical study in Neuropathic pain.
13:00 - 13:15: Global Showcase hosted by Aventacell
hPL Pathogen Reduction Treatment and Risk Assessment
Bill Milligan, VP Business Development, AventaCell Biomedical Corp.; Chair, ISCT Business Models and Investment; Member, ISCT:AABB Joint Working Group on Platelet Lysates , Vancouver, Canada
There is an increasing acceptance of replacing FBS with human platelet lysate as a serum-free supplement for growing cells. Human platelet lysate has proven to be a cost-effective cell culture alternative which provides greater yields of high quality cells when compared to FBS and serum-free mediums. Many clinical trials are being conducted using MSC, fibroblasts, dendritic cells and other cells grown in human platelet lysate. However, as the platelets are collected from allogeneic donors, there are concerns about the potential risk of transmitting pathogens. This session will review a current summary of pathogen reduction treatment (PRT) options for human platelet lysates with a focus on gamma irradiation and the resulting assessment of risk for pathogen transmission
13:15 - 13:30: Global Showcase hosted by Merck
Fast forward to hMSC clinical manufacturing: a novel, xeno-free medium supporting planar and suspension formats for easy scale-up
Kathleen Ongena, Ph.D., Head of Biomaterials and Assays, Cell Therapy Bioprocessing, Merck, USA
The long-term outlook for stem cell therapy predicts an increased need for better defined media and high quality raw materials. Human mesenchymal stromal/stem cells (hMSCs) are an attractive target for clinical study as therapeutic agents. Large scale manufacturing of these adherent-dependent cells necessitates adoption of technologies such as stirred tank bioreactors where suspension culture using microcarriers is enabled. Cell culture media and supplements are critical factors of the scale-up process. Many processes currently include fetal bovine serum (FBS), a commonly-used supplement associated with regulatory, supply, and consistency challenges.
Here, we show the performance of a novel, xeno-free cell culture media formulation developed for the expansion of hMSCs in multiple cell culture platforms. We highlight the growth and characterization of hMSCs in planar, spinner, and stirred tank bioreactor growth platforms. Results indicate the medium delivers improved growth performance compared to a benchmark medium while maintaining expected characteristics of multipotency.
This xeno-free medium developed for hMSC expansion supports the immediate need for suspension-based clinical production as well as future implementation of large scale, commercial manufacturing solutions for allogeneic therapies that will be required following clinical success.
15:15 - 15:30: Global Showcase hosted by Pall
Industrializing Cell and Gene Therapy: Upstream Technologies
Seunghoon Choe, BSc., Meng, Bioprocess Applications Specialist, Pall Biotech, South Korea
As cell and gene therapy develops more and more, there is a great need to scale up the process to produce as many cells and viruses as possible. Current 2D flatware (Roller, Cell Factories etc.) have limitation for this: huge footprint, many aseptic manipulations, many operators, and no real automation nor control. Therefore, alternatives must be found, keeping cost control and ensuring a fast scale up to hit the market quickly.
Pall has multiple technology solutions for upstream cell manufacturing, going over single-use Stirred tank bioreactors that support virus production from suspension cell culture, and adherent cell culture solutions, including multistacked bioreactors, fixed-bed bioreactors, and microcarriers. The focus for this presentation is to give a general introduction of these bioreactors from PALL and how these can be the solutions to your manufacturing and production constraints.
A Novel, Single-Use Bioreactor System for Expansion of Human Mesenchymal Stem/Stromal Cell
Kaitlynn Bayne, Associate Scientist, Pall Biotech, USA
There is a significant need for efficient systems that can be used to generate primary cells and stem cells that can be readily implemented in research laboratories to expedite process development studies and clinical testing. We have previously demonstrated efficient expansion of human mesenchymal stem/stromal cells (hMSC) in the PadReactor® single-use bioreactor system to the 40 L scale. Here we extend these finding by employing these components in a novel bioreactor system. The Allegro™ STR bioreactor is a new stirred tank, single-use bioreactor platform which is scalable, compact, ergonomic and designed to maximize usability and process assurance.
Excellent results were achieved propagating hMSC on microcarriers in the Allegro STR single-use bioreactor over a six day culture period. Cells harvested from microcarriers at the end of the culture reached a cell concentration of 0.79 B cells/L and were 97% viable. A total of 22 B cells were harvested. Importantly, the cells retained critical quality attributes after harvest when examined in standard cell characterization assays. Results achieved in this study were also comparable to those obtained previously in the PadReactor platform. In this study we demonstrated utilization of a novel, single-use platform for efficient generation of high quality cells for process development studies and clinical testing.
17:15 - 18:45: Corporate Symposium hosted by Terumo BCT
Tackling Cell Therapy Manufacturing Challenges with Closed and Automated Solutions
Jim Beltzer, MS, PhD, Sr. Manager, Global Strategic Medical Affairs, Cell Therapy Technologies, Terumo BCT, USA
Wenyan Leong, PhD, Cell Processing Specialist, Cell Therapy Technologies, Terumo BCT, Singapore
With the recent FDA approval of the CAR T-cell therapies Kymriah® from Novartis and Yescarta® from Kite Pharma, there has been a renewed interest in bioprocessing and the manufacturing facilities required to meet the commercial demands for these novel cell therapy products. A successful commercial production process must be scalable, robust and reproducible and must result in a therapy that is affordable, whilst maintaining the functionality and critical quality attributes of the cellular material throughout.
In this session, using CAR T-cell therapy manufacturing as an example, the benefits and impact of automation and flexibility in each manufacturing step in supporting the safety and reliability of the process will be highlighted. Particularly, downstream processing and its challenges will be in focus. Whilst much of the industry effort has been on the upstream process, with emphasis on large-scale cell expansion, in fact, optimization of bioreactor yields often results in downstream process bottlenecks, including harvesting, washing, cell purification, cell concentration, formulation, fill and finish, and preservation. Terumo BCT's new solution for fill and finish will be showcased.
Friday May 31st
7:30-8:30: Breakfast Tutorial Hosted by Invetech
Avoiding the potholes along the pathway from process development to commercial Cell Therapies
Jon Ellis, Manager – Cell Therapy, Invetech, USA
Joanne Kurtzberg, MD, Director, Marcus Center for Cellular Cures, USA and Director, Carolinas Cord Blood Bank at Duke, USA
Dawn Driscoll, MBA PhD GAICD, Chief Executive Officer, Cell Therapies Pty Ltd, Australia
Wen Bo Wang, PhD, Senior Vice President – Technical Operations, Fate Therapeutics, Inc, USA
The emergence of commercially available cell therapies has been an inflection point for our industry. An initial pathway from process development to commercial manufacture has been described, yet there remain many potholes to catch the unwary along the way.
Join us for an insightful discussion on the role that considered automation plays in navigating three of the biggest potholes – productivity of human resources, consistency of manufacturing, and access to capital – helping give your therapy a smooth ride to commercial success.
10:15 - 10:30: Global Showcase hosted by Thermo Fisher Scientific
Bridging the gap from R&D to commercial production with automated, closed and scalable cell processing systems
Rebecca Lim, PhD, Deputy Centre Head, The Ritchie Centre, Research Group Head, Amnion Cell Biology, Research Fellow, Department of Obstetrics, & Gynacology, Monash University, Australia
10:30 - 10:45: Global Showcase hosted by Rooster Bio
Radically Simplifying Scale-up and Clinical Translation of hMSCs and Extracellular Vesicle
Jon A. Rowley, PhD, Chief Product Officer, RoosterBio Inc, USA
Human Mesenchymal Stem/Stromal Cells (hMSCs) are critical raw materials in numerous therapeutic approaches including cell therapies, cell-based gene therapies, tissue and organ engineering, and exosome and extracellular vesicle-based therapies. RoosterBio has greatly simplified all aspects of product development that include hMSCs including discovery research, product development, manufacturing process development as well as tech transfer and cGMP manufacturing of clinical product. Our hMSC Bioprocess Systems facilitate rapid implementation of fed-batch bioreactor scale-up, and can be directly implemented in large scale bioreactor-based EV production. RoosterBio's new EV product innovations enable log enhancements in EV lot size and EV productivity, resetting the cost structure of this exciting new technology segment.
12:30 - 13:30: Corporate Tutorial hosted by Maxcyte
Genome editing iPSCs for enhanced immune compatibility and custom design single nucleotide variations
Akitsu Hotta, PhD, Junior Associate Profesor and principal Investigator at Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan
Induced pluripotent stem cells (iPSCs) have huge potential for disease modeling and regenerative medicine. CRISPR-Cas9 mediated genome editing has revolutionized our ability to modify genomic DNA at a desired locus, however, editing multiple gene loci or altering a single nucleotide is still challenging in iPSCs. We recently showed genome-editing strategies of multiple HLA genes simultaneously for enhancing immune compatibility. More specifically, we disrupted HLA-A and HLA-B genes biallelically to enhance T cell compatibility, and retained at least one allele of HLA-C to suppress NK cell mediated "missing-self" activity. Importantly, HLA-C-retained iPSCs could evade allogenic T and NK cells in vitro and in vivo. We estimate that 12 lines of HLA-C-retained iPSCs combined with HLA-Class II knockout are immunologically compatible with over 90% of the world-wide population, greatly facilitating iPSC-based regenerative medicine applications. I would also like to introduce our efforts to alter single nucleotide in iPSCs for disease modeling or correcting mutations by optimizing state-of-the-art electroporation methods.
12:30 - 12:45: Global Showcase hosted by Cynata Therapeutics
Corporate Product Theatre Hosted By Cynata Therapeutics
Kilian Kelly, PhD, Vice President, Product Development, Cynata Therapeutics, Australia
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale and without the limitation of multiple donors.
Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus™ MSCs into Phase 2 trials for GvHD, critical limb ischemia and osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, diabetic wounds, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.
12:45 - 13:00: Global Showcase hosted by Alliance for Cell and Gene Therapies
An End to End solution for commercializing cell and gene therapies in Australia
Silvio Tiziani, CEO, CCRM Australia
The Australian Alliance of Cell and Gene Therapy (AACGT) is designed to be a platform that provides a single touch point for comprehensive delivery of your cell and gene therapy solutions. The alliance partners each have complementary domain expertise within the cell and gene therapy value chain and an extensive network of partners to provide a complete service from proof of concept, pre-clinical and clinical trials expertise, pilot to commercial manufacturing and commercialisation expertise
ambr® 250 modular bioreactor combined with a new vessel format enables process development of cell therapy products
Nick Masso, Technology Expert Regenerative Medicine, Sartorius Stedim Biotech, USA
At ISCT, Sartorius will launch a new ambr® 250 modular vessel specifically designed for cell therapy process development of sensitive cells. Alongside the new unbaffled single impeller ambr® 250 modular vessel, Sartorius will also launch a low speed version of its ambr® 250 modular mini bioreactor.
The ambr® 250 modular mini bioreactor system combined with the new vessel can be utilized for the process development of sensitive cells for cell therapy applications.
We will present how this system has been designed for:
Innovative parallel automated cell culturing
Scalable process development for T-cells and different types of stem cells
Consistent growth of cell therapy relevant cell types
13:15 - 13:30: Global Showcase hosted by FUJIFILM
Challenges in developing an off-the-shelf cell therapy for ACLF and NASH
Jeff Pinxteren, PhD, VP of Operations at Promethera Biosciences, Belgium
Background & Aim: Promethera is a biopharma company focused on the research, development and commercialization of stem cell-based therapies and technologies for acute and chronic liver diseases. Our lead clinical program, an allogenic human liver derived mesenchymal stem cell product derived from our patented cell technology platform HepaStem, is currently being used in Phase IIa clinical trials for ACLF (acute on chronic liver failure) with the company also preparing clinical trials for NASH. Non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic liver diseases (NAFLD), is one of the prominent liver diseases worldwide. There is currently no approved drug for its treatment and liver transplantation is the only therapeutic approach for advanced NASH. Mesenchymal stem cells (MSCs) are promising candidates to modulate the proinflammatory and pro-fibrogenic environment of chronic liver because of their immunomodulatory properties. Recent data obtained in preclinical models of early and advanced stage NASH provided significant evidences to open new phase I/II clinical studies in NASH.
Methods, Results & Conclusion: The dosing for this indication is likely to be in the order of 100 million cells per infusion. Large numbers of cells thus need to be manufactured and using standard cell culture techniques would make it too expensive and labour intensive. A standard expansion protocol in flasks or cell factories is an open process, and therefore run in expensive clean rooms to avoid the risk of contamination. We have explored several state-of-the art-bioreactor systems, and various types of microcarriers in stirred tanks from different manufacturers. We have tested these systems to optimize the complete workflow of HepaStem culture, including stem cell isolation from livers and expansion up to the scale of many clinical doses. Quality control and comparability studies were performed to verify that the characteristics of HepaStem cells harvested from the different procedures were maintained. We have built a production platform, almost entirely in closed system, that can provide the large numbers of clinical doses that would be needed for the treatment of NASH. This platform functions with a strong reduction of human labour and it also modular and flexible to anticipate growing demand. In parallel we have developed serum-free and xenofree culture methods to be able to abandon the use of animal-derived products, for the related risks and because animal sera become scarce and expensive.
TABLE TITLE:
The dosing for this indication is likely to be in the order of 100 million cells per infusion. Large numbers of cells thus need to be manufactured and using standard cell culture techniques would make it too expensive and labour intensive. A standard expansion protocol in flasks or cell factories is an open process, and therefore run in expensive clean rooms to avoid the risk of contamination. We have explored several state-of-the art-bioreactor systems, and various types of microcarriers in stirred tanks from different manufacturers. We have tested these systems to optimize the complete workflow of HepaStem culture, including stem cell isolation from livers and expansion up to the scale of many clinical doses. Quality control and comparability studies were performed to verify that the characteristics of HepaStem cells harvested from the different procedures were maintained. We have built a production platform, almost entirely in closed system, that can provide the large numbers of clinical doses that would be needed for the treatment of NASH. This platform functions with a strong reduction of human labour and it also modular and flexible to anticipate growing demand. In parallel we have developed serum-free and xenofree culture methods to be able to abandon the use of animal-derived products, for the related risks and because animal sera become scarce and expensive.
15:15 - 15:30: Global Showcase hosted by Sartorius
Next Generation Cellular Therapeutic Technologies: Rapid Detection of Bacterial Contamination
Dr. Glenn Manning, Application Specialist, Sartorius Australia Pty Ltd, Australia
Sterility is a critical quality attribute (CQA) of cellular therapeutics. Since microbial contamination of cell therapy products can potentially result in the deaths of the recipients, sterility testing is a critical component of the release testing for any cell therapy product. The current compendial sterility test takes 14 days before contamination can be ruled out with certainty, which is too long for short shelf life cellular therapeutics and especially for autologous cell therapies intended to treat terminally ill patients. As a result there is an increasing demand for growth-independent
rapid assays. Therefore a detection system consisting of the highly efficient DNA extraction protocol Microsart® Bacteria Extraction followed by the real time PCR assay Microsart® ATMP Bacteria has been developed. A validation study was designed to evaluate the bacterial detection capability. The study was set up to meet requirements of the European Pharmacopeia chapter 5.1.6.
17:00 - 19:00: Corporate Symposium hosted by Novartis Pharmaceuticals
CAR-T – from concept to clinic
Simon Harrison, MBBS, MRCP (UK), FRCPath (UK), FRACP, PhD, Director of Clinical Aphaeresis, Disease Group Lead; Myeloma, Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital Victorian Comprehensive Cancer Centre, Principal Fellow, Sir Peter MacCallum Dept of Oncology, Melbourne University
Bruce Levine, PhD, University if Pennsylvania, United States
Transitioning from academic CAR-T cell production to industry collaboration
Peter Homlan, Novartis, United States
Building blocks for institutional preparation of CAR-T
Michael Dichinson, Peter MacCallum Cancer Centre, Australia
PMCC experience with delivering CAR-T cell therapy in Australia
Catherine Bollard, MBBS, Children's National Medical Center, United States
CAR-T use in Lymphoma
The concept behind chimeric antigen receptor (CAR)-T cell therapy is simple – enhance the body's own immune system to recognise and attack cancer cells. Transforming this elegant concept from academia into a commercially available therapy manufactured for each individual patient is rather more challenging.
Join leading international and Australian clinicians in CAR-T therapy to hear the latest science and evolution of individualised CAR-T therapy. This symposium explores CAR-T therapy from initial development to the treatment of patients.
The journey includes the transition from academia to commercial production, regulatory requirements for treatment centres to deliver CAR-T therapy as well as real-world experience from a major Australian treatment centre.
Saturday June 1
12:15 - 13:15 Corporate Tutorial hosted by Roche CustomBiotech
Rapid microbiological methods in meeting unique QC and product specific validation needs of advanced therapy manufacturing
Evonne R. Fearnot, MSBME Marketing Manager, Roche CustomBiotech, United States
Alexey Bersenev, MD, PhD, Director of Cell Therapy Processing and Advanced Cell Therapy Laboratories at Yale – New Haven Hospital, Yale University, United States
Sowmya Viswanathan, PhD Affiliate Scientist, Krembil Research Institute, University Health Network; Assistant Professor, Institute of Biomaterials and Biomedical Engineering, University of Toronto; Assistant Professor, Department of Medicine, University of Toronto; Regulatory and Manufacturing Advisor, OIRM, Canada
Rapid microbiological methods (RMMs) are essential for state-of-the-art manufacturing efficiency of advanced therapies because traditional testing methods do not provide shorter testing timelines and lower sample volume utilization. Some advanced therapies involve a manufacturing process and release timeline of just a few days making third-party testing impractical. There are ways to incorporate RMMs for QC testing, such as using a nucleic acid amplification technique as an alternative mycoplasma testing system after appropriate product-specific validation inhouse. Leveraging available validation data facilitates a regulatory abbreviated qualification plan for RMMs. Several myths impede advanced therapy manufacturers from adopting these RMMs for QC testing. This session is intended to dispel these myths with accurate information and real-world experience.
© 2019 ISCT. All rights reserved.
ISCT, and the ISCT logo are registered service marks of the International Society for Cellular Therapy.
Kangaroo, 2018 © Wendy Rix/Copyright Agency, 2018


text:
Vincent A. Cicirello has published over 40 refereed journal and conference papers on topics including artificial intelligence, genetic algorithms, evolutionary computation, swarm intelligence, machine learning, multi-agent systems, computer-aided engineering, computer-aided design, and computer science education.
The publications are organized by year of publication:
Abstracts and publication data are found through the title links. Links are also provided to full-text in pdf format (PDF links), and to the publisher's definitive version (DOI links or PUB links) for most papers. The BIB links provide bibtex entries.
2020 (Top of the page)
Optimizing the Modified Lam Annealing Schedule.
Vincent A. Cicirello.
Industrial Networks and Intelligent Systems, 7(25), Article e1, December 2020. doi:10.4108/eai.16-12-2020.167653
[PDF] [BIB] [DOI]
Chips-n-Salsa: A Java Library of Customizable, Hybridizable, Iterative, Parallel, Stochastic, and Self-Adaptive Local Search Algorithms.
Journal of Open Source Software, 5(52), Article 2448, August 2020. doi:10.21105/joss.02448
Kendall Tau Sequence Distance: Extending Kendall Tau from Ranks to Sequences.
Industrial Networks and Intelligent Systems, 7(23), Article e1, April 2020. doi:10.4108/eai.13-7-2018.163925
[PDF] [BIB] [DOI] [arXiv]
Classification of Permutation Distance Metrics for Fitness Landscape Analysis.
In Proceedings of the 11th International Conference on Bio-inspired Information and Communication Technologies, pages 81-97. Springer Nature, March 2019. doi:10.1007/978-3-030-24202-2_7
JavaPermutationTools: A Java Library of Permutation Distance Metrics.
Journal of Open Source Software, 3(31), Article 950, November 2018. doi:10.21105/joss.00950
Impact of Random Number Generation on Parallel Genetic Algorithms.
In Proceedings of the Thirty-First International Florida Artificial Intelligence Research Society Conference, pages 2-7. AAAI Press, May 2018.
Design, Configuration, Implementation, and Performance of a Simple 32 Core Raspberry Pi Cluster.
arXiv preprint arXiv:1708.05264 [cs.DC], August 2017.
[PDF] [BIB] [arXiv]
Variable Annealing Length and Parallelism in Simulated Annealing.
In Proceedings of the Tenth International Symposium on Combinatorial Search (SoCS 2017), pages 2-10. AAAI Press, June 2017.
[PDF] [BIB] [PUB] [arXiv]
Searching for a Permutation in a Haystack.
In Proceedings of the Tenth International Symposium on Combinatorial Search (SoCS 2017), pages 177. AAAI Press, June 2017.
Previously Published Papers Track.
[PDF] [BIB]
Student Developed Computer Science Educational Tools as Software Engineering Course Projects.
Journal of Computing Sciences in Colleges, 32(3): 55-61, January 2017.
The Permutation in a Haystack Problem and the Calculus of Search Landscapes.
IEEE Transactions on Evolutionary Computation, 20(3): 434-446, June 2016. doi:10.1109/TEVC.2015.2477284
Weighted Tardiness Scheduling with Sequence-Dependent Setups: A Benchmark Library.
Harvard Dataverse, doi:10.7910/DVN/VHA0VQ, June 2016.
[ZIP] [BIB] [DOI]
Genetic Algorithm Parameter Control: Application to Scheduling with Sequence-Dependent Setups.
In Proceedings of the 9th International Conference on Bio-inspired Information and Communications Technologies, pages 136-143. EAI, December 2015.
On the Effects of Window-Limits on the Distance Profiles of Permutation Neighborhood Operators.
In Proceedings of the 8th International Conference on Bio-inspired Information and Communications Technologies, pages 28-35. EAI, December 2014.
A Flexible and Extensible Approach to Automated CAD/CAM Format Classification.
Vincent A. Cicirello and William C. Regli.
Computers & Graphics, 37(5): 484-495, August 2013. doi:10.1016/j.cag.2013.03.007
Special Section on 3D Object Retrieval.
A CS Unplugged Activity for the Online Classroom.
Journal of Computing Sciences in Colleges, 28(6): 162-168, June 2013.
Experiences with a Real Projects for Real Clients Course on Software Engineering at a Liberal Arts Institution.
Journal of Computing Sciences in Colleges, 28(6): 50-56, June 2013.
Profiling the Distance Characteristics of Mutation Operators for Permutation-Based Genetic Algorithms.
Vincent A. Cicirello and Robert Cernera.
In Proceedings of the Twenty-Sixth International Florida Artificial Intelligence Research Society Conference, pages 46-51. AAAI Press, May 2013.
Method for Comparing Solid Models.
William C. Regli and Vincent A. Cicirello.
U.S. Patent #7,761,265 B2, July 2010.
Heuristic Sequencing Crossover: Integrating Problem Dependent Heuristic Knowledge into a Genetic Algorithm.
In Proceedings of the Twenty-Third International Florida Artificial Intelligence Research Society Conference, FLAIRS-23, pages 14-19. AAAI Press, May 2010.
Collective Bin Packing: An Active Learning Exercise.
On Self-Selected Pairing in CS1: Who Pairs with Whom?.
On the Role and Effectiveness of Pop Quizzes in CS1.
In Proceedings of the 40th ACM Technical Symposium on Computer Science Education, SIGCSE'09, pages 286-290. ACM Press, March 2009. doi:10.1145/1539024.1508971
Also published in ACM SIGCSE Inroads, 41(1):286-290, March 2009.
Weighted Tardiness Scheduling with Sequence-Dependent Setups: A Benchmark Problem for Soft Computing.
In Applications of Soft Computing: Updating the State of the Art, volume 52 of Advances in Soft Computing, pages 189-198. Springer, 2009. doi:10.1007/978-3-540-88079-0_19
Statistical Models of Multistart Randomized Heuristic Search Performance.
Technical Report, Richard Stockton College, Galloway, NJ, May 2008.
Presented at the 40th Symposium on the Interface: Computing Science and Statistics (conference without proceedings), in Durham, NC, sponsored by the National Institute of Statistical Sciences. Full paper here as Technical Report.
A Study of Wireless Security Privacy and Forensics.
Demetrios Roubos, Shawn Casler, James Hedigan, Ryan Shaw, Suvineetha Herath, David Costantino, Vincent Cicirello, Robert Kachur, and Ajantha Herath.
CCSC:SC Student Paper E-Journal, 1, April 2008.
An Interdisciplinary Course on Artificial Intelligence Designed for a Liberal Arts Curriculum.
Journal of Computing Sciences in Colleges, 23(3): 120-127, January 2008.
On the Design of an Adaptive Simulated Annealing Algorithm.
In Proceedings of the International Conference on Principles and Practice of Constraint Programming First Workshop on Autonomous Search. AAAI Press, September 2007.
The Challenge of Sequence-Dependent Setups: Proposal for a Scheduling Competition Track on One Machine Sequencing Problems.
In Proceedings of the International Conference on Automated Planning and Scheduling (ICAPS) Workshop on Scheduling a Scheduling Competition. AAAI Press, September 2007.
Non-Wrapping Order Crossover: An Order Preserving Crossover Operator that Respects Absolute Position.
In Proceedings of the Genetic and Evolutionary Computation Conference (GECCO'06), volume 2, pages 1125-1131. ACM Press, July 2006. doi:10.1145/1143997.1144177
Nominated for the Genetic Algorithms Track Best Paper Award.
Service-Based Computing on MANETs: Enabling Dynamic Interoperability of First Responders.
Joseph Kopena, Evan Sultanik, Gaurav Naik, Iris Howley, Maxim Peysakhov, Vincent A. Cicirello, Moshe Kam, and William Regli.
IEEE Intelligent Systems, 20(5): 17-25, September/October 2005. doi:10.1109/MIS.2005.94
Special Issue on Artificial Intelligence for Homeland Security.
Designing Decentralized Software for a Wireless Network Environment: Evaluating Patterns of Mobility for a Mobile Agent Swarm.
Vincent A. Cicirello, Andrew Mroczkowski, and William Regli.
In Proceedings of the 2005 IEEE Second Symposium on Multi-Agent Security and Survivability, pages 49-57. August 2005. doi:10.1109/MASSUR.2005.1507047
Agent Survivability Through Power Awareness.
Maxim Peysakhov, Andrew Mroczkowski, Leonardo Urbano, Jacob Warren, Vincent A. Cicirello, William Regli, and Moshe Kam.
The Max K-Armed Bandit: A New Model of Exploration Applied to Search Heuristic Selection.
Vincent A. Cicirello and Stephen F. Smith.
In The Proceedings of the Twentieth National Conference on Artificial Intelligence, volume 3, pages 1355-1361. AAAI Press, July 2005.
Winner of the AAAI 2005 Outstanding Paper Award.
The AI Technologies of the Philadelphia Area Urban Wireless Network Testbed.
Gustave Anderson, Andrew Burnheimer, Vincent Cicirello, David Dorsey, Chris Dugan, Iris Howley, Moshe Kam, Joseph Kopena, Rob Lass, Kris Malfettone, Andy Mroczkowski, Gaurav Naik, Max Peysakhov, Brian Pyles, William Regli, Evan Sultanik, James Thiel, Kyle Usbeck, Dan Venutolo, and Marc Winners.
Network Awareness and the Philadelphia Area Urban Wireless Network Testbed.
Joseph B. Kopena, Vincent A. Cicirello, Maxim Peysakhov, Kris Malfettone, Andrew Mroczkowski, Gaurav Naik, Evan Sultanik, Moshe Kam, and William C. Regli.
In AI Technologies for Homeland Security: Papers from the 2005 AAAI Spring Symposium, pages 70-75. AAAI Press, March 2005.
Enhancing Stochastic Search Performance by Value-Biased Randomization of Heuristics.
Journal of Heuristics, 11(1): 5-34, January 2005. doi:10.1007/s10732-005-6997-8
Designing Dependable Agent Systems for Mobile Wireless Networks.
Vincent A. Cicirello, Max Peysakhov, Gustave Anderson, Gaurav Naik, Kenneth Tsang, William C. Regli, and Moshe Kam.
Special Issue on Dependable Agent Systems.
Heuristic Selection for Stochastic Search Optimization: Modeling Solution Quality by Extreme Value Theory.
In Principles and Practice of Constraint Programming - CP 2004: 10th International Conference, Proceedings, volume LNCS 3258 of Lecture Notes in Computer Science, pages 197-211. Springer-Verlag, September/October 2004. doi:10.1007/978-3-540-30201-8_17
Engineering Multi-Agent Systems.
Donovan Artz, Vincent A. Cicirello, William Regli, and Moshe Kam.
In Proceedings of the 2004 IEEE First Symposium on Multi-Agent Security and Survivability, pages 100-107. August 2004. doi:10.1109/MASSUR.2004.1368423
Demonstration of the Secure Wireless Agent Testbed (SWAT).
Gustave Anderson, Andrew Burnheimer, Vincent Cicirello, David Dorsey, Saturnino Garcia, Moshe Kam, Joseph Kopena, Kris Malfettone, Andy Mroczkowski, Gaurav Naik, Max Peysakhov, William Regli, Joshua Shaffer, Evan Sultanik, Kenneth Tsang, Leonardo Urbano, Kyle Usbeck, and Jacob Warren.
In Proceedings of the Third International Joint Conference on Autonomous Agents and Multi-Agent Systems (AAMAS-2004), volume 3, pages 1214-1215. IEEE Computer Society, July 2004. doi:10.1109/AAMAS.2004.10265
Intelligent Systems Demonstration: The Secure Wireless Agent Testbed (SWAT).
In Proceedings of the Nineteenth National Conference on Artificial Intelligence and the Sixteenth Innovative Applications of Artificial Intelligence Conference, pages 1004-1005. AAAI Press, July 2004.
In The 14th International Conference on Automated Planning and Scheduling. June 2004.
Wasp-like Agents for Distributed Factory Coordination.
Autonomous Agents and Multi-Agent Systems, 8(3): 237-266, May 2004. doi:10.1023/B:AGNT.0000018807.12771.60
Ecology Based Decentralized Agent Management System.
Maxim D. Peysakhov, Vincent A. Cicirello, and William C. Regli.
In Formal Approaches to Agent-Based Systems: Third International Workshop, FAABS 2004, Revised Selected Papers, volume LNCS 3228 of Lecture Notes in Computer Science, pages 1-11. Springer-Verlag, April 2004. doi:10.1007/978-3-540-30960-4_1
The Secure Wireless Agent Testbed.
Vincent Cicirello, Moshe Kam, William Regli, Rafael Alonso, and Jeffrey Bloom.
In The DARPA Proposers Day Workshop: Defense Against Cyber Attacks on Mobile Ad Hoc Networks. February 2004.
Invited Presentation.
[BIB]
Task Allocation Using a Distributed Market-Based Planning Mechanism.
Dani Goldberg, Vincent Cicirello, M. Bernardine Dias, Reid Simmons, Stephen Smith, and Anthony Stentz.
In Proceedings of the Second International Joint Conference on Autonomous Agents and Multiagent Systems (AAMAS-2003), pages 996-997. ACM Press, July 2003. doi:10.1145/860575.860763
Boosting Stochastic Problem Solvers Through Online Self-Analysis of Performance.
PhD thesis, The Robotics Institute, School of Computer Science, Carnegie Mellon University, Pittsburgh, PA, July 2003.
Market-Based Multi-Robot Planning in a Distributed Layered Architecture.
In Multi-Robot Systems: From Swarms to Intelligent Automata: Proceedings of the 2003 International Workshop on Multi-Robot Systems, volume 2, pages 27-38. Kluwer Academic Publishers, March 2003.
Technical Report, Intelligent Coordination and Logistics Laboratory, Robotics Institute, Carnegie Mellon University, Pittsburgh, PA, February 2003.
An Approach to a Feature-based Comparison of Solid Models of Machined Parts.
Artificial Intelligence for Engineering Design, Analysis and Manufacturing, 16(5): 385-399, November 2002. doi:10.1017/S0890060402165048
A Distributed Layered Architecture for Mobile Robot Coordination: Application to Space Exploration.
Dani Goldberg, Vincent Cicirello, M. Bernardine Dias, Reid Simmons, Stephen Smith, Trey Smith, and Anthony Stentz.
In The 3rd International NASA Workshop on Planning and Scheduling for Space. October 2002.
Amplification of Search Performance through Randomization of Heuristics.
In Principles and Practice of Constraint Programming - CP 2002: 8th International Conference, Proceedings, volume LNCS 2470 of Lecture Notes in Computer Science, pages 124-138. Springer-Verlag, September 2002. doi:10.1007/3-540-46135-3_9
WHISTLING: Wasp Behavior Inspired Stochastic Sampling.
In The 2002 SIAM Annual Meeting and SIAM 50th Anniversary, Final Program and Abstracts, pages 228. SIAM, July 2002.
Distributed Coordination of Resources via Wasp-like Agents.
In Innovative Concepts for Agent-Based Systems: First International Workshop on Radical Agent Concepts, WRAC-2002, volume LNAI 2564 of Lecture Notes in Artificial Intelligence, pages 71-80. Springer-Verlag, January 2002. doi:10.1007/978-3-540-45173-0_5
Technical Report CMU-RI-TR-01-39, Robotics Institute, Carnegie Mellon University, Pittsburgh, PA, December 2001.
Randomizing Dispatch Scheduling Policies.
In Using Uncertainty Within Computation: Papers from the 2001 AAAI Fall Symposium, pages 30-37. AAAI Press, November 2001.
A Game-Theoretic Analysis of Multi-Agent Systems for Shop Floor Routing.
Technical Report CMU-RI-TR-01-28, Robotics Institute, Carnegie Mellon University, Pittsburgh, PA, September 2001.
Improved Routing Wasps for Distributed Factory Control.
In The IJCAI-01 Workshop on Artificial Intelligence and Manufacturing, Working Notes, pages 26-32. August 2001.
Insect Societies and Manufacturing.
Wasp Nests for Self-Configurable Factories.
In Proceedings of the Fifth International Conference on Autonomous Agents, pages 473-480. ACM Press, May/June 2001. doi:10.1145/375735.376420
Machining Feature-Based Comparison of Mechanical Parts.
In Proceedings of the International Conference on Shape Modeling and Applications, pages 176-185. IEEE Computer Society Press, May 2001. doi:10.1109/SMA.2001.923388
Ant Colony Control for Autonomous Decentralized Shop Floor Routing.
In ISADS-2001: Proceedings of the Fifth International Symposium on Autonomous Decentralized Systems, pages 383-390. IEEE Computer Society Press, March 2001. doi:10.1109/ISADS.2001.917443
Modeling GA Performance for Control Parameter Optimization.
In GECCO-2000: Proceedings of the Genetic and Evolutionary Computation Conference, pages 235-242. Morgan Kaufmann Publishers, July 2000.
Managing Digital Libraries for Computer-Aided Design.
Computer-Aided Design, 32(2): 119-132, February 2000. doi:10.1016/S0010-4485(99)00095-0
The Engineering Design Repositories Project.
William C. Regli, Lisa Anthony, Vincent Cicirello, Jon John, Xiaoli Qin, Yuriy Shapirshteyn, and Vera Zaychik.
In National Science Foundation Design and Manufacturing Grantees Meeting. January 2000.
Resolving Non-Uniqueness in Design Feature Histories.
In Proceedings of the Fifth ACM/SIGGRAPH Symposium on Solid Modeling and Applications, pages 76-84. ACM Press, June 1999. doi:10.1145/304012.304020
Intelligent Retrieval of Solid Models.
Master's thesis, Department of Mathematics and Computer Science, Drexel University, Philadelphia, PA, June 1999.
Intelligent Retrieval of CAD Models.
In The Eleventh Annual Sigma Xi Research Symposium, pages 125. Drexel University and MCP Hahnemann University, May 1999.
Abstract and Poster Presentation.
Survey of Graph Matching Algorithms.
Technical Report, Geometric and Intelligent Computing Laboratory, Drexel University, Philadelphia, PA, March 1999.
Representations and Algorithms for CAD/CAM Digital Libraries.
In SIAM Workshop on Mathematical Foundations for Features in Computer-Aided Design and Manufacturing, pages 34. October 1998.

redpajama_set_name: RedPajamaCommonCrawl


text:
Gay marriage backers target New England
By Valerie Richardson - The Washington Times - Sunday, January 4, 2009
Two New England states have already legalized same-sex marriage, and a Boston-based advocacy group wants to see the other four join them.
Gay and Lesbian Advocates and Defenders, known as GLAD, has launched a first-of-its-kind regional campaign aimed at winning approval for same-sex marriage in the six-state New England region by 2012.
Same-sex marriage is already legal in Connecticut and Massachusetts, a result of court decisions in cases brought by GLAD lawyers. The 2003 Massachusetts decision was the first in the nation, while the Connecticut ruling went into effect Nov. 12.
"We can make New England a marriage-equality zone by strategically combining existing legal, electoral and on-the-ground know-how to fast-track marriage in every New England state," GLAD Executive Director Lee Swislow said.
"By 2012, we not only can have marriage equality throughout New England, we can have a road map for the rest of the country," she said.
But proponents of traditional marriage say the organization may be setting itself up for defeat. Even in liberal New England, persuading four more states to sign off on same-sex marriage won't be a slam dunk, especially if it involves moving through the state legislatures, said Peter Sprigg, vice president for policy at the Family Research Council.
"I'm skeptical that they'll be able to win same-sex marriage in all six states by 2012. Public opinion continues to be much more resistant than homosexual activists are willing to admit," Mr. Sprigg said. "We saw that in California with Proposition 8."
Indeed, the gay-marriage movement is still smarting from its stinging defeat in November, when California voters passed Proposition 8, a state constitutional amendment that overturned a state Supreme Court decision legalizing same-sex marriage.
That wasn't the impetus behind Six by Twelve. The campaign is pegged to the fifth anniversary of Goodridge v. Department of Public Health, the Massachusetts case. But advocates did say it was important to remain active in Proposition 8's aftermath.
"The timing [after Proposition 8] wasn't part of the plan, because the plan for Six by Twelve preceded Proposition 8. But I can see how folks would get comfort from this after what happened in California," said Alison Cashin, GLAD's manager of public education. "It's a big defeat, but California is one state."
California joined Florida and Arizona in approving ballot measures in November, bringing the number of states that define marriage as the union of a man and a woman in their constitutions to 29. An additional 15 states define marriage that way in state statutes.
"While they may be stepping up their efforts, pro-family groups are also stepping up our efforts in defense of traditional marriage," Mr. Sprigg said.
The New England states have been open to marriage alternatives.
Vermont and New Hampshire both offer civil unions for same-sex couples, while Maine extends "a few of the benefits accorded to married couples" through domestic partnerships, according to GLAD. Rhode Island also allows state employees to list gay domestic partners for health care and other benefits.
While the issue has enjoyed considerable success in the courts, same-sex marriage has never won through the state legislative process. The California legislature did approve same-sex marriage bills twice, but both were vetoed by Gov. Arnold Schwarzenegger.
That could change when Vermont's legislature convenes later this month. The Six by Twelve campaign's best bet for a quick victory lies in Montpelier, where lawmakers are already planning to introduce same-sex marriage legislation.
A similar bill was introduced last year, but legislators elected instead to form a commission to study the issue. The panel held hearings throughout the state, where people testifying in favor of same-sex marriage routinely outnumbered opponents. The commission ultimately issued a report supporting gay marriage while stopping short of recommending it. Still, the issue's advocates say the panel helped lay the groundwork for this year's debate.
"A lot of legislators were nervous about this issue, so we saw this as an opportunity to educate Vermonters in rural areas and also in the cities," said Beth Robinson, chairwoman of Vermont Freedom to Marry. "This session, we're not looking for an alternative to moving it [a bill] to the floor. We're asking them to do the right thing now."
The bill could run into trouble with Gov. Jim Douglas, a Republican who doesn't support same-sex marriage, according to his spokesman.
"He believes our civil-union law provides equality in same-sex relationships," spokesman Steve Wark said.
However, the governor, who won re-election handily in November, has never said that he would veto a bill, leaving same-sex marriage advocates with a sliver of hope.
"Given that he's a red governor in a blue state, he's managed to do that by being fair-minded," Ms. Robinson said. "Our own belief is that he'll do the right thing."


text:
Conservatives keep winning battles in their war on same-sex marriage (Canada!)
Globe & Mail - Toronto, Canada ^ | May 31, 2005 | JOHN IBBITSON
Posted on 05/31/2005 5:59:48 PM PDT by GMMAC
GLOBE AND MAIL , 2005.05.31
JOHN IBBITSON
Conservatives keep winning battles in their war on same-sex marriage
Vic Toews was settling into the fifth hour of his filibuster yesterday when the Liberals conceded defeat. It was a very good day for social conservatives in Canada.
Bill C-38, the legislation legalizing same-sex marriage nationwide, has turned into a war of manoeuvres, with the Conservatives outmanoeuvring the Liberals at every turn. Yesterday, the Tories manoeuvred to virtually guarantee that the bill will not become law until at least October, if then.
The government wants same-sex legislation passed into law as quickly as possible, to get it out of the way and to heal the rift the issue has caused within the party. Thirty-five Liberal MPs have voted against the bill, and there are concerns that one or two cabinet ministers could join the rebels on third reading, even if it costs them their portfolios.
The Conservatives, on the other hand, want to delay the legislation, because they oppose it in principle and because they believe it is a wedge issue that can be used against the Liberals in an election.
Meanwhile, the Defend Marriage Trust, a coalition of religious and social conservative organizations, is pressing both the Conservatives and the dissident Liberal MPs to do everything in their power to delay passage of C-38 until Parliament dissolves for an election and the bill dies.
In their latest manoeuvre, the Conservatives tried to hold the bill up in committee by insisting that 22 additional speakers be added to the list of witnesses. When the Liberals refused and tried to force the committee to report on the bill by June 9, Mr. Toews began his filibuster, which wiped out two sittings of the committee.
Yesterday afternoon, Paul Macklin, the justice parliamentary secretary, met Karen Redman, the Liberal Whip, just before Question Period.
They agreed that Mr. Toews had them over a barrel, and some sort of compromise would have to be worked out. Two hours later, as Mr.
Toews launched into Day 3 of his filibuster, Mr. Macklin asked for a brief time out. All parties huddled together for a few minutes and, when the session resumed, there was a deal. Mr. Toews got his witnesses, and the committee will delay its report until June 16.
That leaves only three sitting days to debate the bill before Parliament is scheduled to rise for the summer. Some high-placed Liberals remain confident they can still push the legislation through before the summer break. They could invoke closure, or have the House sit round the clock, or extend the sitting.
If they try any of these tactics, however, they risk a backbench revolt. Pat O'Brien has already threatened to quit the caucus if the same-sex legislation is rammed through the House. Yesterday, he warned his party's leadership against any attempts at hasty action.
"I am less than satisfied that they are doing it at breakneck speed," he said in an interview. If the government tries to rush a vote on third reading, "I think there will be a major problem in the caucus. I know I would have a major problem." Unless the government, which still hangs onto the confidence of the House by a thread, is willing to risk this kind of internal rebellion, it will have to give up its June deadline, and let debate on the bill resume when the House returns in late September. Then it will be up to the Conservatives to decide how long to prolong the debate, before letting C-38 come forward for a final vote.
Even then, nothing is certain. The Senate must also pass this bill, and there is word coming from the Other Place that a few senators may take steps to delay passage.
Link Byfield, one of the leaders in the fight against same-sex marriage, once predicted: "The single factor that will do more to determine the outcome of this fight is which side lasts longer, and can keep up the momentum." Exactly.
TOPICS: Canada; Culture/Society; Foreign Affairs; Government
KEYWORDS: canada; cary; corruption; cults; gayagenda; homosexualagenda; idolatry; liberals; perverts; samesexmarriage
Note: for anyone unaware of same, the despicable Globe is the de facto unofficial mouthpiece of the Martinite and radical homosexual wings of the Liberal Party of Canada.
Ergo, publishing this column musta been somewhat less than a labor of love - LOL!
Further Note: url furnished is to a copy of the article on the "defendmarriage.ca" website as the vile Globe is now running a pay-to-view operation.
1 posted on 05/31/2005 5:59:49 PM PDT by GMMAC
To: GMMAC
I hate to tell you but the Muslims will kill you before the gays...take that from a fellow Scot.
2 posted on 05/31/2005 6:01:31 PM PDT by Cornpone (Who Dares Wins -- Defame Islam Today -- Tell the Truth About Muhammad)
To: fanfan; Pikamax; Former Proud Canadian; Great Dane; Alberta's Child; headsonpikes; coteblanche; ...
"TRUE BLUE"
~ CPC PING! ~
God Bless Vic Toews! ~ E-mail
3 posted on 05/31/2005 6:05:20 PM PDT by GMMAC (paraphrasing Parrish: "damned Liberals, I hate those bastards!")
To: Cornpone
Yes, but what if they are "gay" Muslims.
4 posted on 05/31/2005 6:10:59 PM PDT by NavVet ("Benedict Arnold was wounded in battle fighting for America, but no one remembers him for that.")
bttt
5 posted on 05/31/2005 6:37:44 PM PDT by aberaussie
To: NavVet
They either deep in the closet or deep in the ground. In Islam those are the only two options for someone who is "different".
6 posted on 05/31/2005 7:02:20 PM PDT by Squawk 8888 (End dependence on foreign oil- put a Slowpoke in your basement)
I certainly wish you all well-- I've covered this subject until I was, frankly, just sick of it- you either "get" how divisive this issue is to civil society, or you don't... it is a real poison pill:
-A Gay ( or not! ) Old Time- GM links--
...and I say this as an older person who has had gay relatives, employees, friends and neighbors. I don't much care what consenting adults do in private... but when you start dragging the rest of society ( to say nothing of the children ) into it, it's time to draw the line.
7 posted on 06/01/2005 1:54:07 AM PDT by backhoe (-30-)
To: Squawk 8888
I actually read a funny article in which some so-called Islamic Scholar was blaming the existence of Palestinian homosexuals on the Jews.
8 posted on 06/01/2005 2:04:55 AM PDT by NavVet ("Benedict Arnold was wounded in battle fighting for America, but no one remembers him for that.")
Comment #9 Removed by Moderator
To: Observer of Life
I think it may to time to invoke the poison pill that was quietly discussed about a year ago. If the government abolishes civil marriage then the pervs can be "equal" without forcing the rest of us to celebrate behaviour we consider repugnant.
10 posted on 06/01/2005 6:22:01 AM PDT by Squawk 8888 (End dependence on foreign oil- put a Slowpoke in your basement)
To: Observer of Life; fanfan; Pikamax; Former Proud Canadian; Great Dane; Alberta's Child; ...
It's amazing that someone so busy kissing the butts of Canada's judicial dictators even has time to spy on conservative forums and freedom-loving people - much less post! Take a hint: trolls and toadies of totalitarianism aren't welcome hereabouts.
Section 33 of the Charter - "the not withstanding clause" - was included to be used specifically to rein-in activist Judges and make them properly subservient to the peoples' duly elected representatives. In fact, had it not been included, your socialist buddy Trudeau plainly would have faced open revolt back in 1982.
Funny how you leftist hypocrites foolishly think you can claim that every word of this vile, imposed document is somehow sacred -EXCEPT SECTION 33! - while applauding Judges who imagine it includes supposed "rights" which both aren't found within it and which often Parliament specifically excluded.
Put bluntly: a day is coming when either Parliament calls Judges to account or those of us who rightly reject anti-majority tyranny will do so by any means at our disposal.
OR - as Dr. William D. Gairdner (echoing St. Augustine!) states it:
"Our Choice: A Free Society under a Just Law or an 'Equal' Society Under Corrupt Law."
11 posted on 06/01/2005 6:53:43 AM PDT by GMMAC (paraphrasing Parrish: "damned Liberals, I hate those bastards!")
If you think the notwithstanding clause will be used in this case, you're smoking something.
When in danger,
Or in doubt,
Run in circles,
Scream and shout.
If slagging people merely because they don't see the point of wasting energy on what is a done deal turns your crank, have at it, Sunshine.
But don't presume to call me names.
The notwithstanding clause has been used precisely once. It was used by the Provincial government of Quebec, that government that complained so bitterly that the people of Quebec were somehow "unrepresented" in repatriation. The people of Quebec who were perfectly well represented by their MPs. I'm not buying the "unrepresented" party line. They used it to get Bill 101 past the courts, to make it legal to discriminate against English speakers.
12 posted on 06/01/2005 6:50:57 PM PDT by Observer of Life
"Grow up."
??????? - Seemingly, it's pretty apparent from the thread who started with the profanity, defeatism and activist judge worshiping.
Keep it up newbie and you won't last long around here.
BTW, "Observer of Life" - your screen name pretty much describes a spy doesn't it?
13 posted on 06/01/2005 7:30:14 PM PDT by GMMAC (paraphrasing Parrish: "damned Liberals, I hate those bastards!")


text:
Family, friends hold vigil for man killed four years ago; killer never found
DeAndre Allen was shot 11 times
Updated: 11:04 PM CST Dec 26, 2020
Caroline Reinwald
HER SON WHO WAS KILLED FOUR YEARS AGO. >> FOUR YEARS AGO TO THE DAY, SHANNON ALLEN'S SON WAS SHOT AND KILLED AT 39TH IN MICHIGAN. POLICE STILL HAVE NOT FOUND HIS KILLER. >> MY CHILD WAS NOT JUST SHOT ONCE, MY CHILD WAS SHOT A TOTAL OF 11 TIMES. THREE TO THE HEAD, ONE TO THE NECK, ONE FINGER HANGING OFF, MULTIPLE SHOTS THROUGH HIS STOMACH AND ALL THROUGHOUT HIS BACK. I DESERVE TO KNOW WHY. >> FRIENDS AND FAMILY RELEASED SILVER AND BLUE BALLOONS IN HIS HONOR, THEN ORANGE BALLOONS TO HONOR OTHER VICTIMS OF HOMICIDES IN THIS RECORD-BREAKING YEAR. ACCORDING TO THE MILWAUKEE HEALTH DEPARTMENT VIOLENCE DEPARTMENT, IN 2020 WE HAD 189 HOMICIDES. THAT IS NEARLY DOUBLED COMPARED TO THIS TIME LAST YEAR WHEN WE HAD 96 HOMICIDES. IT IS THE MOST KILLINGS THAT MILWAUKEE HAS HAD SINCE 2015. >> THE PANDEMIC HAS ILLUMINATED THE FACT THAT WHEN COMMUNITIES DON'T HAVE WHAT THEY NEED, THERE IS A LEVEL OF DESPERATION, DESPAIR AND TRAUMA. >> HE SAYS A SPIKE IN GUN PURCHASES IN MARCH LED TO A PREVALENCE OF GUNS IN MILWAUKEE CARS AND HOMES. A PANDEMIC HAS PUT AN EXTREME AMOUNT OF STRESS ON PEOPLE. >> GIVEN THE FACT THAT OTHER CITIES AROUND THE COUNTRY HAVE EXPERIENCED THE SAME LEVEL OF HISTORIC OF VIOLENCE, WE HOPE THAT THIS IS AN ANOMALY. ENDING 2020 IN REFLECTION WITH HOWTO MOVE FORWARD AFTER A YEAR OF HISTORIC VIOLENC
A mother is grieving for her son who was killed on this day four years ago. Police are still searching for the killer. DeAndre Allen was shot 11 times on this day in 2016.Police found the 27-year-old dead in a secluded area in the Miller Valley, near 39th and Michigan streets.Allen left behind six children. His mother said police have not arrested anyone in Allen's case. She and Allen's family and friends gathered at the site of his death for an emotional vigil."My child was not just shot once my child was shot a total of 11 times. I deserve to know why," said Shannon Allen, Deandre Allen's mother. Allen said she is grieving for those families as well as her own."This has to stop. Every year we're doing this. It has to stop," Allen said. The Office of Violence Prevention said there have been 189 homicides this year. That is nearly double compared to the 96 homicides this time last year. It is the most homicides in Milwaukee since 2015. "The pandemic has illuminated the fact that when communities don't have what they need, there's a level of desperation, despair and trauma that exists," said Reggie Moore, director of the Office of Violence Prevention. Moore said the surge of gun purchases in March has led to a prevalence of firearms in cars and homes in Milwaukee. Plus, the pandemic has put an extreme amount of stress on people. "Quality housing, livable wages in terms of employment, access to capitol in terms of entrepreneurship, those are really all the things we need to double down on if we want to see a change long term in our community," Moore said.
A mother is grieving for her son who was killed on this day four years ago.
Police are still searching for the killer.
DeAndre Allen was shot 11 times on this day in 2016.
Police found the 27-year-old dead in a secluded area in the Miller Valley, near 39th and Michigan streets.
Allen left behind six children.
His mother said police have not arrested anyone in Allen's case.
She and Allen's family and friends gathered at the site of his death for an emotional vigil.
"My child was not just shot once my child was shot a total of 11 times. I deserve to know why," said Shannon Allen, Deandre Allen's mother.
Allen said she is grieving for those families as well as her own.
"This has to stop. Every year we're doing this. It has to stop," Allen said.
The Office of Violence Prevention said there have been 189 homicides this year. That is nearly double compared to the 96 homicides this time last year.
It is the most homicides in Milwaukee since 2015.
"The pandemic has illuminated the fact that when communities don't have what they need, there's a level of desperation, despair and trauma that exists," said Reggie Moore, director of the Office of Violence Prevention.
Moore said the surge of gun purchases in March has led to a prevalence of firearms in cars and homes in Milwaukee. Plus, the pandemic has put an extreme amount of stress on people.
"Quality housing, livable wages in terms of employment, access to capitol in terms of entrepreneurship, those are really all the things we need to double down on if we want to see a change long term in our community," Moore said.
'Fighting for justice:' Mom pleads for information on anniversary of son's shooting death


text:
Home > Professors > Grants Programs Overview > Discovery Frontiers Call for Proposals: Advancing Big Data Science in Genomics Research
Professors Grants Programs Overview Innovation Chairs and Faculty Support Overview Research Tools and Instruments and Infrastructure Programs Direct Deposit Resource Videos Contact Newsletter Frequently Asked Questions Eligibility Application Deadlines and Notification of Decision Policies and Guidelines Tri-Agency Financial Administration Guide Summary of Changes Discovery Grants Information Centre Grants Information Sessions A World of Discoveries
Discovery Frontiers Call for Proposals:
Advancing Big Data Science in Genomics Research
Value Up to $1.5 million per year for four years + Up to $1 million for infrastructure
Application Deadline May 1, 2013 – Letter of Intent
June 14, 2013 – Invitation to Apply
November 15, 2013 – Application, if invited to apply
Anticipated Number of Invitations to Apply 5-8
Anticipated Notice of Award February 2014
Anticipated Start Date February 2014
How to Apply See below
Form 100 – Personal Data Form
Form 101 – Application for a Grant
To create or access an application, select On-line System Login.
To view forms and instructions, select PDF Forms and Instructions.
Contact See below
Researchers Invited to Apply
Discovery Frontiers (DF) grants support a limited number of large international activities, opportunities or projects that are of high priority in the context of advanced research in Canada. These will be led by teams of world-class Canadian researchers and will generate substantial benefits for Canada.
This initiative aims to bring together groups of researchers in new ways to address a major research challenge. The teams will incorporate new and emerging ideas and will combine their complementary expertise to conduct transformative, paradigm-changing research.
Massive amounts of data are being generated by genomics1 research across all life science sectors. The lack of efficient tools and methodologies available to effectively mine, rapidly access and efficiently analyse vast quantities of genomic information and integrate it with other data sets is a major challenge for the research community.
To address this global research challenge, the Natural Sciences and Engineering Research Council of Canada (NSERC), Genome Canada, the Canadian Institutes of Health Research (CIHR) and the Canada Foundation for Innovation (CFI) will partner on this 2013 DF call for proposals, which will focus on advancing big data science in genomics research. This initiative will support the development of tools and methodologies to integrate currently available complex data sets in the fields of 'omics sciences with each other, as well as with phenotypic data and data from other related fields of biological sciences. This DF call for proposals will build on past and ongoing investments in this area, the most recent being the Bioinformatics and Computational Biology Request for Applications launched in June 2012 by Genome Canada and CIHR.
The objective of this 2013 DF call is to support the establishment of a major initiative with strong international linkages. The initiative will develop tools and methodologies for integrating various types of 'omics data (e.g., genomics, proteomics, metabolomics) with: 1) each other; 2) phenotypic data collected from different organisms of study; or 3) data sets originating from diverse scientific disciplines/fields, including but not limited to imaging, ontology/semantics, biophysics, environmental science and evolution.
As appropriate for the proposed research, this initiative will bring together experts from a wide range of disciplines, including computer science, engineering, mathematics, machine learning, statistics, genomics and the relevant scientific disciplines being studied.
Together, they will focus on exploring and developing diverse computational and mathematical approaches and techniques, including, but not limited to, creating new algorithms, information systems, Web technologies, artificial intelligence, software engineering, data mining, image processing, modeling and simulation. Clear linkages to the international community must be demonstrated through, for example, the participation of international scientists in the initiative, in international collaborations or in relevant international initiatives.
Approaches used will emphasize bold initiatives and interdisciplinary thinking, with potential for major breakthroughs and impact across a range of scientific disciplines.
It is expected that the end product of this DF grant will further strengthen Canada's leadership role and capacity in the area of genomics research and produce valuable knowledge that will be disseminated in the appropriate fashion to maximize its impact. This initiative will provide a training opportunity for highly qualified personnel in a focused, multidisciplinary national and international environment. Most importantly, this initiative is intended to build synergies with, but not duplicate, existing large-scale genomic research funding initiatives. The outcome and impacts of DF grants should be transformative, not merely incremental.
All applications must describe, with supporting evidence, the deliverable(s) that will be realized by the end of the project and include a plan that describes how the deliverables from the research will be transferred, disseminated, used, and/or applied to realize the benefits to the research community. Although the open source/open access model currently informs the development of methodologies within the area of biological science research data analysis, applicants may articulate alternative options for community availability and downstream development as long as the dissemination plan ensures maximum community uptake. Preference will be given to applications with a high potential for community impact and/or uptake regardless of the type of dissemination plan proposed.
Projects must have a strategy for knowledge and technology transfer to all stakeholders and the general public, as appropriate, that conforms to NSERC's Policy on Intellectual Property (IP). The details of this strategy do not need to be outlined in the application documents, but may be requested at the time of award.
Funds Available
NSERC, Genome Canada, CIHR and the CFI plan to award one DF grant through this call, at a total funding level of $1.5 million per year for four years for the direct research costs, plus an additional $1 million for costs related to infrastructure, if required. Applicants invited to submit a full application will be eligible to receive a development grant (up to $25,000 per approved LOI), up to a maximum of $200,000 for the competition. The contribution from each partner is as follows:
NSERC – up to $800,000 per year,
Genome Canada – up to $500,000 per year,
CIHR – up to $250,000 per year,
CFI – one-time award of up to $1,000,000 for infrastructure costs, with an additional 30% towards eligible operating and maintenance costs of the infrastructure.
Funds from each agency will be used for eligible expenses as defined in the relevant guidelines. For NSERC and CIHR, refer to the Use of Grant Funds section of the Tri-Agency Financial Administration Guide. For Genome Canada, refer to the Genome Canada Guidelines for Funding Research Projects. For CFI, refer to the CFI Policy and Program Guide.
Additional Guidelines
The following are ineligible costs:
costs associated with generating new data, and
salaries, benefits and associated costs for the performance of wet lab work.
High-Performance Computing (HPC) infrastructure
Although funding for high-performance computing (HPC) infrastructure may be requested from the CFI, the CFI requires that, if possible, the HPC infrastructure be housed and managed by Compute Canada. Consultation with Compute Canada is therefore required prior to application. A determination of whether Compute Canada services can or cannot be used for the proposed initiative will be required at the time of full application. This determination can take the form of a formal letter of support from Compute Canada.
Although this determination is not required at the Letter of Intent stage, applicants considering a request for HPC infrastructure are strongly encouraged to contact and begin discussions with Compute Canada as early as possible.
For the purposes of these guidelines, high-performance computing (HPC) infrastructure encompasses any computing system with capabilities larger or more powerful than typically available in a standard desktop system. Such HPC infrastructure normally includes systems or resources such as the following:
capacity or throughput computing,
capability computing supporting tightly coupled, fine grained applications,
shared memory systems,
systems supporting very large memory requirements,
high-performance storage,
long-term storage,
computing using specialized accelerators including GP-CPU and others,
high-performance visualization systems, and
systems suitable for computational steering and interactive use.
Typically, such systems cost more than $50,000.
In each case, the term HPC encompasses the software and environment needed for a given discipline to effectively utilize these types of infrastructure and encompasses needs such as high levels of data security and integrity as may be required by specific disciplines or researchers.
For your application to be eligible, the applicant and co-applicants must meet NSERC, Genome Canada and CIHR eligibility criteria and be at an institution eligible to receive NSERC, Genome Canada, and CIHR funds. Applicants applying for infrastructure funding must be affiliated with an institution that is eligible to receive CFI funds. Applicants are reminded that the CFI provides research infrastructure funds to institutions, not individual researchers or teams of researchers. Applicants applying for infrastructure funding must therefore contact the CFI liaison officer at their institution prior to drafting Letters of Intent.
In addition to meeting the funders' general eligibility criteria, proposals must demonstrate that the project responds to the objectives of the Discovery Frontiers initiative.
NSERC will work with Genome Canada, CIHR and CFI throughout the competition process. Applicants are required to apply for funding through NSERC. The application process has two steps: Letter of Intent (LOI) and Full Application.
Applicants may also request up to $1 million in infrastructure funding from the CFI. Note that a request for infrastructure support from the CFI is not a requirement for the application to NSERC, but that infrastructure funding will not be provided separately from the Discovery Frontiers program application.
Applicants begin by submitting a Letter of Intent. The Letter of Intent must include a cover page (one page), a research proposal (maximum five pages) and biographical information on the team (maximum two pages). All documents should follow the NSERC presentation standards.
The cover page must include:
the project title,
a list of up to 10 keywords,
an approximate budget request, by project year, for direct costs of research,
an approximate budget request for infrastructure, for teams applying for infrastructure,
the applicant's name, affiliation, telephone number and email address, and
a list of all co-applicants, with affiliation and email address.
The research proposal should include:
a description of the main research challenges and activities,
a discussion of anticipated participation by collaborators, such as international researchers and government scientists, and their roles,
a discussion of anticipated outcomes and benefits,
a description of the plans for training of highly qualified personnel, and
a high level summary of the major budget items with justification, including any infrastructure.
The biographical information should contain short biographies of the applicant and co-applicants and their areas of expertise.
The Letter of Intent should be saved as a single PDF document, and uploaded to NSERC's secure portalbefore the deadline.
Note that details concerning proposals that are successful at the LOI stage will be published on NSERC's Web site.
Review Procedures and Selection Criteria
A multidisciplinary international committee will review the Letters of Intent. The review process at the LOI stage is intended to select those proposals that best fit the program objectives and best address the LOI review criteria with an emphasis on the merit of the proposal. The review criteria are as follows:
merit of the research proposal;
novelty of the proposed approach
potential to be transformative and have high international impact
potential to create new fields of research
potential to extend and/or complement national and international work in the area
appropriateness of the methods and approaches (including handling of data and resources) in terms of the research objectives
feasibility of the research given the projected resources and time-lines
degree of integration across disciplines and with international collaborators
relevance to the end users identified, including potential application beyond the field of genomics
anticipated outcomes and benefits to the wider community
excellence of the applicants and complementarity of expertise;
potential for value-added training of highly qualified personnel.
Applicants who are invited to submit a full proposal will be given further instructions on submission details at the time of invitation.
Full proposals will be reviewed through a rigorous independent peer review process, undertaken by a multidisciplinary international committee, to assess their eligibility, research merit and potential for benefits to the research community as well as to ensure that sound management and financial practices are implemented. Excellence in terms of the review criteria at the very highest of international standards must be demonstrated for funding to be awarded to the most meritorious proposal.
The applications will be reviewed using the following criteria. Please note that the descriptive phrases that follow the criteria below are not all-inclusive.
Research Context and Originality
To what extent does the proposed research lead, extend and/or complement national and international work in the area?
To what extent does the proposed research reflect creative, original thinking?
To what extent is the research relevant to the end users identified?
To what extent will the proposed tools or methodologies increase the productivity of genomics research?
To what extent could the proposed research have an impact beyond the field of genomics research?
Research Plans
How appropriate are the methods and approaches (including handling of data and resources) in terms of the research objectives?
How feasible is the research given the projected resources and timelines?
How appropriate is the expertise of the research team in terms of realizing the research goals?
How effectively will the project bring together expertise from complementary disciplines?
How suitable are the available facilities and equipment?
To what extent have the applicants identified appropriate deliverables in terms of their potential to have practical applicability to the research community?
What is the probability that the deliverables will be realized by the end of the funding period?
Expected Benefits
How significant are the anticipated benefits described in the proposal to the genomics community?
What is the probability that the benefits will be realized by the research community within a short time-frame after the end of the project?
What is the potential for the initiative to achieve excellence in the training of highly qualified personnel?
Strategy for Realizing Benefits
How appropriate is the plan for access to, and dissemination of, the tools and methodologies developed?
Quality of the plan describing how the deliverables from the research will be transferred, disseminated, used, and/or applied to realize the benefits.
How high is the potential for community impact and/or uptake, regardless of the type of dissemination plan proposed?
Expertise for Realizing Benefits
To what extent are likely end-users involved in the project and the strategy to realize benefits?
Management and Finance
Management Plans and Expertise
How well does the management plan cover project governance, accountabilities of personnel, and processes for decision-making on research direction and strategy for realizing benefits?
How convincing is the management plan in terms of coordination of current and future partnerships?
How realistic is the project schedule?
To what extent do the project leaders have experience in managing projects with multi-disciplinary teams involving research and the application of results?
How good are the plans to ensure that an adequate number of highly qualified personnel—both support personnel (e .g., technicians) and trainees (e.g., post-doctoral fellows)—are available to meet the needs of the proposed research through recruitment and/or training?
Budget and Expenditure Controls
How reasonable is the proposed budget in terms of the anticipated level of effort and deliverables?
To what extent does the proposal provide assurance that expenditures from a funded project would be closely and critically monitored?
For proposals that contain infrastructure requests from the CFI, the following criteria will also be considered:
To what extent is the infrastructure necessary and appropriate to conduct the research or technology development programs?
To what extent will the use of the infrastructure be maximized within and among institutions and sectors (private, public and non-profit)?
To what extent will the proposed infrastructure be effectively managed, operated and maintained for its useful life?
Regular reporting will be required for this award. A scientific review committee will assess scientific progress annually. The review will provide information regarding the progress of the project according to the proposed timelines. The scientific review committee can also provide advice to the project team if it feels that changes to project milestones or direction are necessary. NSERC, Genome Canada and CIHR will use the scientific review committee's report to determine whether funding for the project will be continued, reduced or terminated.
Financial reports will also be reviewed annually by all funding partners.
Specific details on the format and schedule and other required information will be available at the time of award.
Dave Bowen
Discovery Frontiers
350 Albert St.
K1A 1H5
E-mail: dave.bowen@nserc-crsng.gc.ca
1 The term genomics is defined here as the comprehensive study, using high throughput technologies, of the genetic information of a cell or organism, including the function of specific genes, their interactions with each other and the activation and suppression of genes. For purposes of describing Genome Canada's mandate, it also includes related disciplines, such as bioinformatics, epigenomics, metabolomics, metagenomics, nutrigenomics, pharmacogenomics, proteomics and transcriptomics.


C.15134 - Sweeping Southern Long Lake Views! Beautifully updated end unit with crown molding, granite and stainless steel kitchen, upgraded fixtures, electric and manual storm shutters, lots of tile and Plantation shutters. Enjoy a spacious and private lakefront lanai. Great amenities at the L'ambiance and Pelican Bay.


text:
A Disphyma a szegfűvirágúak (Caryophyllales) rendjébe, ezen belül a kristályvirágfélék (Aizoaceae) családjába tartozó nemzetség.

Előfordulásuk
A Disphyma-fajok természetes körülmények között a Dél-afrikai Köztársaság területén, valamint Ausztráliában találhatók meg. Tasmania szigetén is jelen van ez a növénynemzetség, azonban az Északi területről hiányzik. Az ember betelepítette a Brit-szigetre, Franciaországba, az Ibériai-félszigetre, Marokkóba, valamint az Azori-, a Baleár- és a Kanári-szigetekre is.

Rendszerezés
A nemzetségbe az alábbi 4 faj tartozik:

Disphyma australe (Sol. ex Aiton) J.M.Black
Disphyma crassifolium (L.) L.Bolus - típusfaj
Disphyma dunsdonii L.Bolus
Disphyma papillatum Chinnock

Források
Disphyma N.E.Br. Plants of the World Online
Brown, N.E., 1925: Gardeners' Chronicle. London, Ser. III. lxxviii. 433, in clavi.
Hassler, M. 2018. Disphyma. World Plants: Synonymic Checklists of the Vascular Plants of the World. In: Roskovh, Y., Abucay, L., Orrell, T., Nicolson, D., Bailly, N., Kirk, P., Bourgoin, T., DeWalt, R.E., Decock, W., De Wever, A., Nieukerken, E. van, Zarucchi, J. & Penev, L., eds. 2018. Species 2000 & ITIS Catalogue of Life. Published on the internet. Accessed: 2018 Jul. 06. Reference page.
International Plant Names Index. 2018. Disphyma. Published online. Accessed Jul. 06 2018.

Kristályvirágfélék
Növénynemzetségek

redpajama_set_name: RedPajamaWikipedia


Inspired to help other women enjoy the financial security she had found Wendy launched WomenOptionTraders.Com and began giving online classes.
A natural-born teacher, her following grew quickly and so did requests for an easy-to-understand book on options. So in 2009 Wendy co-authored, with Virginia McCullough the book Option Trading In Your Spare Time - A Guide to Financial Independence for Women.
Click here for a sneak peek at Wendy Kirkland's P3 Book.
Click here for a quick view of some of Wendy's featured charts.
Please click here to view Wendy's current StockCharts.com charts.


text:
Yo-Yo Ma: 'I'm turning 60 and I want…'
The cellist will reach his 60th birthday on October 7 and he's telling jokes about ageing, après-ski and senior bus passes in an interview with Martin Steinberg for the forthcoming November issue of Strings magazine. But he's also got major issues on his mind.
Where did our high school subjects come from? Our studies are from 1910, so [do] we need to reboot that? How does art fit into that, how does that fit into arts funding and science funding? What are we educating our children for? Is it a transactional thing? Do you pay that money in order to get better jobs or is there something about education that is different?
« London student wins Valencia piano competition
By request: The Hebrew prayers for Pope Francis »
We would be so lucky if students now emerged from high school as skilled and knowledgable as the average student of 1910. For one thing they would all be attending live concerts! We continue to benefit daily from the fruits of their toil, and yet feel smug enough to deride an older generation? This smacks of SJW-ism.
milka says:
you can't top the interview for banality….yawn
I don't know about Europe, the UK, or Asia, but in the US our high school subjects are certainly not what they were in 1910. "Home Ec" is all but gone, along with shop. Typing is gone everywhere, and shorthand bit the dust 30 years ago. We've added a plethora of computer classes. Alas, schooling isn't what it used to be though. Students today have miserable handwriting. They can't do basic arithmetic in their heads. Spelling, even of simple words, is lacking. Their knowledge of history is pathetic. Their knowledge of the humanities is horrifying: many know nothing of Shakespeare, Beethoven, and company. The young have little interest in classical music, opera, or intelligent cinema.
CDH says:
They are not taught writing: they are taught that all they will ever need to know how to write is their signatures. They are not taught grammar or spelling — I think politics has made rules of language somehow "oppressive" or "sexist," and anyway there is spellcheck and, in good word processing programmes, grammar-check. They are not taught to compute: they are taught how to use calculators. They are taught minimal reading: I know a young woman completing her DOCTORATE in literature without having done Shakespeare. She opted to pass every time it was on offer because "I don't like drama."
So we are back to the three Rs: and nobody is left who knows how to teach them.
How in God's name, which is also an unfamiliar one to most of those who might once have been loosely categorised as "Christian" (can't speak for others), can people with such "educations" be expected to appreciate classical music, opera or intelligent cinema? Video games, blockbusters, apps: these are their "culture." But are they only a generation or two away from not having anyone to provide content?
William Safford says:
"The children now love luxury. They have bad manners, contempt for authority; they show disrespect for elders and love chatter in place of exercise."
― Socrates
william osborne says:
And we remember what happened to Athens, and eventually all of Greece…


When you specify an SSH test, you must have the SSH wrapper installed on the client. The test will most likely fail if this wrapper has not been installed.
Backups will fail if the last directory specified in the path as the backup destination has a space in the name. Please ensure that the backup destination directory specified within your LBackup configurations has no space. The LBackup team are investigating this issue.
If you are backing up to certain network mounted file systems on Mac OS X then the backup will probably not work. This is because LBackup would like to preserve the permissions and other meta-data which may not be supported by the remote file system or the connection to the remote file system. If you have a suggestion on how to resolve this then please contact us.
If your log file has a space or other character which requires escaping in the path name then it will not work. A bug fix for this issue, is slated for the next release. It has already been fixed in the latest alpha.
The extended attributes of symbolic links may not be preserved. This issue is being investigated.
Resource forks under Mac OS are always being updated. A discussion about this issue is taking place at the arRsync home page.
The backup of AppleScript Applications and Droplets is not working on machine running Mac OS 10.3.9 or earlier. This is due to the custom version of RSync. This bug is one reason the LBackup project since release 0.9.8q5 has moved to the standard version of RSync which ships with Mac OS X. If you have AppleScript Applications which must be backed up and you are using the custom version of Rsync, then it is reccomended that archives of these Applications are made. LBackup will then store the archive correctly. Another work around is to save these scripts as Application Bundles rather than Applications.
ASR (Apple Software Restore) disk images created with CCC on intel based systems appear as corrupted when copied by RSync. This issue may affect more than just images created with CCC, or it could be an argument missing. More information will be posted as it becomes available.
The binary available for download has been tested on 10.2.9, 10.3.9, 10.4.11 and 10.5.0 and it has been tested on both Intel and PPC architectures. However please be aware that it is a PPC binary. If you have complied an universal binary version of rsync which then please consider contributing this binary to the LBackup project. In the mean time you may want to compile your own version of rsync version 3.
Under Mac OS 10.4.7 there seems to be an intermittent issue with rsync. This issue is discussed further here. Information relating to this issue will be posted as it becomes available. If you are having this problem with the built in version of rsync, then it is recommended that you set the following option to your LBackup your configuration file.
If LBackup needs to traverse more than 99 symbolic links while attempting to load a configuration file it will stop. The assumption is that there is some sort of symbolic link loop setup in the file system. If this becomes a problem for you simply edit the source code and increase the maximum number of allowed symbolic links which may be traversed.


text:
Regional Overview – Asia 02 July 2018
Posted: 3 July 2018 | Category: Analysis
AnalysisAsiaCivilians At RiskCurrent HotspotsFocus On MilitiasPolitical StabilityRemote ViolenceRioting And ProtestsViolence Against Civilians
Last week was marked by major protests in Afghanistan, ongoing election turmoil in Pakistan, and militant violence in Indonesia. In Afghanistan, following the end of the ceasefire, levels of political violence further increased by 20% compared to the previous week, which is a total hike of over 78% compared to the week of the ceasefire. In light of this spike in violence, people across 16 provinces took to the streets last week to demand peace negotiations between the Taliban and the Afghan government and an end to the war.
In Pakistan, tensions related to the upcoming general elections – scheduled for July 25 – continue to contribute to a large number of non-violent protests as well as violent attacks. In Sindh Province, Sindh Taraqi Pasand Party (STPP) workers were kidnapped by unidentified assailants. In Punjab Province, guards of the city mayor from the Pakistan Muslim League-Nawaz (PML-N) opened fire onto Pakistan Tehreek-i-Insaf (PTI) workers in a hospital.
In Indonesia, militant violence by both Jemaah Ansharut Daulah (JAD) and Papuan separatists were reported last week. The police killed one JAD militant on June 22 and two JAD militants on June 23, when they resisted arrest in West Java province. Meanwhile in Papua province on June 25, separatists shot at an aircraft chartered by the Mobile Brigade (Brimob) while landing at Keneyam Airport. The attack reportedly left several policemen injured and three civilians dead. On June 27, separatists shot at two boats carrying voters and government officials in Torere district, reportedly killing three people.
In India, levels of political violence remained high in the state of Jammu & Kashmir as state forces continue to carry out cordon and search operations (CASOs) that have reportedly left dead several militants as well as local youth who pelted stones at government forces to support the militants. In the state of Jharkhand, seven members of the police were reportedly killed when Maoist rebels exploded an improvised explosive device (IED). People in several parts of the country also took to the streets to protest against recent rape cases of minor girls.
In Bangladesh, unidentified militants ambushed a police task force, killing a former Jamaat-ul-Mujahideen Bangladesh (JMB) leader who was accompanying the task force during a search operation in Sirajdikhan town. In Sri Lanka, an army corporal was shot and injured by an unidentified group in Colombo city.
(Data on Philippines, Thailand and Myanmar have not yet been released; trends are hence not explored above.)
Daniela Pollmann
Daniela Pollmann is ACLED's Program Coordinator. Ms Pollmann holds a MA in Conflict, Security and Development from the University of Sussex with focus on peace processes. She has previous work experience in the social sector in Uganda and India where her work focused on women empowerment, child protection and anti-human trafficking. She is currently stationed in New Delhi, India.
Categories: Analysis, Asia, Civilians At Risk, Current Hotspots, Focus On Militias, Political Stability, Remote Violence, Rioting And Protests, Violence Against Civilians 3 July 2018
Tags: AfghanistanBangladeshCambodiaIndiaIndonesiaLaosNepalPakistanVietnam
PreviousPrevious post:Regional Overview – Middle East 02 July 2018NextNext post:Regional Overview – Africa 02 July 2018
Ukraine Crisis: 3-9 December 2022